Viavi Solutions Inc.
$8.20B- Market cap
- $8.60B
- Debt
- +$244.80M
- Cash
- −$649.80M
Capital structure 97% equity / 3% debt · EV / Revenue 5.40x · EV / EBITDA 66.86x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: VIAV stock price at discount vs VRTX $34.86 current versus $70.97 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at VRTX's multiple
Implied fair value · at VIAV's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: VIAV FY 2026 (ended Jun 27, 2026) · VRTX FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 97% equity / 3% debt · EV / Revenue 5.40x · EV / EBITDA 66.86x
Capital structure 97% equity / 3% debt · EV / Revenue 11.34x · EV / EBITDA 27.98x
VRTX carries the larger enterprise value at $136.04B against $8.20B; VIAV trades on the lower EV / Revenue multiple (5.40x vs 11.34x); VRTX on the lower EV / EBITDA (27.98x vs 66.86x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Viavi Solutions Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
VERTEX PHARMACEUTICALS INC / MA · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.17x
0.23x
Net debt / EBITDA
Leverage against operating earnings
-3.30x
-0.49x
Cash and equivalents
Liquid reserves on the balance sheet
$649.80M
$6.61B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Broadcom Inc.
VIAV vs AVGO
TEXAS INSTRUMENTS INC
VIAV vs TXN
ANALOG DEVICES INC
VIAV vs ADI
SKYWORKS SOLUTIONS, INC.
VIAV vs SWKS
Qorvo, Inc.
VIAV vs QRVO
Marvell Technology, Inc.
VIAV vs MRVL
AMGEN INC
VIAV vs AMGN
Gilead Sciences, Inc.
VIAV vs GILD
BIOGEN INC.
VIAV vs BIIB
Moderna, Inc.
VIAV vs MRNA
Illumina, Inc.
VIAV vs ILMN
$244.80M
$4.23B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.